Cyberonics
This article was originally published in The Gray Sheet
Executive Summary
Vagus nerve stimulation system developer raises $45 mil. in a private placement of 2.5 mil. common shares at $18 each. Proceeds will be used to fund ongoing and future clinical trials in depression, obesity and anxiety, the firm reports Feb. 14. Company's 21-center, 210-patient U.S. pivotal study for depression has enrolled 136 patients to date. Pilot studies in obesity and Alzheimer's are underway, and the firm also has an approved IDE for a 30-patient, four-center pilot study set to begin in fiscal 2001 of left cervical vagus nerve stimulation for three major anxiety disorders. US Bancorp Piper Jaffray acted as placement agent for the financing
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.